FWP
SPRY icon

FAS Wealth Partners’s ARS Pharmaceuticals SPRY Stock Holding History

FAS Wealth Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
214,507
+9,100
+4% +$78.3K 0.09% 147
2026
Q1 		$1.65M Buy
205,407
+3,000
+1% +$28.8K 0.1% 143
2025
Q4 		$2.36M Buy
202,407
+1,787
+0.9% +$17.4K 0.15% 118
2025
Q3 		$2.02M Buy
200,620
+51,460
+34% +$739K 0.14% 126
2025
Q2 		$2.6M Buy
149,160
+9,625
+7% +$139K 0.19% 103
2025
Q1 		$1.76M Buy
139,535
+44,830
+47% +$539K 0.14% 119
2024
Q4 		$999K Buy
94,705
+9,850
+12% +$138K 0.08% 147
2024
Q3 		$1.23M Buy
84,855
+17,199
+25% +$205K 0.1% 136
2024
Q2 		$576K Buy
67,656
+7,186
+12% +$63.8K 0.05% 187
2024
Q1 		$618K Buy
60,470
+14,500
+32% +$108K 0.05% 180
2023
Q4 		$252K Hold
45,970
– – 0.02% 266
2023
Q3 		$174K Buy
45,970
+11,720
+34% +$76.9K 0.02% 279
2023
Q2 		$229K Buy
+34,250
New +$229K 0.03% 242

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FAS Wealth Partners's SPRY Position: Q2 2026 in Review

FAS Wealth Partners increased its ARS Pharmaceuticals (SPRY) stake by 4.4% in Q2 2026, buying an estimated $78.3K and bringing the position to 214,507 shares worth $1.72M. The position accounts for 0.09% of the portfolio, ranked #147.

FAS Wealth Partners first reported a position in SPRY in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.6M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • FAS Wealth Partners held 214,507 shares of ARS Pharmaceuticals worth $1.72M as of Q2 2026.
  • FAS Wealth Partners bought 9,100 ARS Pharmaceuticals shares in Q2 2026, an estimated $78.3K.
  • ARS Pharmaceuticals made up 0.09% of FAS Wealth Partners's portfolio in Q2 2026, its #147 holding.
  • FAS Wealth Partners first reported a position in ARS Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • FAS Wealth Partners's ARS Pharmaceuticals position peaked at $2.6M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.